Multiple myeloma(MM)is the second most common hematologic malignant tumor.Standard holistic treatment model and new drug-based regimens have greatly improved the survival of patients with MM;however,minimal residual disease(MRD)causes relapse in most patients.Therefore,combining MRD testing on the basis of traditional serological efficacy evaluation is necessary to achieve a more accurate assessment of the patient's disease status.At present,next-generation flow cytometry(NGF)and next-generation sequencing(NGS)are the mainstream technologies for detecting MRD based on bone marrow samples.To standardize and normalize MRD detection,the expert group discussed and formulated Chinese expert consensus on the application of NGF and NGS technology for bone marrow MRD detection in patients with MM.
NETL
NSTL
万方数据
